FR2740339B1
(fr)
*
|
1995-10-26 |
1997-12-05 |
Oreal |
Utilisation d'au moins un inhibiteur de no-synthase dans le traitement des peaux sensibles
|
US6369272B1
(en)
|
1997-01-13 |
2002-04-09 |
Glaxosmithkline |
Nitric oxide synthase inhibitors
|
US6620848B2
(en)
|
1997-01-13 |
2003-09-16 |
Smithkline Beecham Corporation |
Nitric oxide synthase inhibitors
|
WO1998033379A1
(en)
*
|
1997-02-04 |
1998-08-06 |
The General Hospital Corporation |
A novel method for treating epidermal or dermal conditions
|
AU8647198A
(en)
*
|
1997-08-12 |
1999-03-01 |
Chugai Seiyaku Kabushiki Kaisha |
Remedies for diseases associated with bone resorption
|
HUP0101467A3
(en)
*
|
1998-03-11 |
2003-03-28 |
G D Searle & Co Skokie |
Halogenated amidino amino acid derivatives useful as nitric monoxide synthase inhibitors
|
US6284735B1
(en)
*
|
1998-04-28 |
2001-09-04 |
Lion Bioscience Ag |
HP-3228 and related peptides to treat sexual dysfunction
|
US6534503B1
(en)
|
1998-04-28 |
2003-03-18 |
Lion Bioscience Ag |
Melanocortin receptor-3 ligands to treat sexual dysfunction
|
WO1999055679A1
(en)
|
1998-04-28 |
1999-11-04 |
Trega Biosciences, Inc. |
Isoquinoline compound melanocortin receptor ligands and methods of using same
|
GB9811599D0
(en)
|
1998-05-30 |
1998-07-29 |
Glaxo Group Ltd |
Nitric oxide synthase inhibitors
|
AU6605800A
(en)
*
|
1999-07-16 |
2001-02-05 |
Trega Biosciences, Inc. |
Melanocortin receptor-3 ligands to treat sexual dysfunction
|
US6403830B2
(en)
*
|
2000-03-24 |
2002-06-11 |
Pharmacia Corporation |
Amidino compound and salts thereof useful as nitric oxide synthase inhibitors
|
AR034120A1
(es)
*
|
2000-04-13 |
2004-02-04 |
Pharmacia Corp |
Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico
|
GB0031179D0
(en)
*
|
2000-12-21 |
2001-01-31 |
Glaxo Group Ltd |
Nitric oxide synthase inhibitors
|
DE10111050A1
(de)
*
|
2001-03-06 |
2002-09-12 |
Beiersdorf Ag |
Verwendung von Substanzen, die verhindern, daß die NO-Synthase des warmblütigenOrganismus ihre Wirkung entfaltet, zur Herstellung von kosmetischewn oder dermatologischen Zubereitungen zur Behandlung und/oder Prophylaxe unerwünschter Hautpigmentierung
|
DE10111049A1
(de)
*
|
2001-03-06 |
2002-09-12 |
Beiersdorf Ag |
Verwendung von Substanzen, die verhindern, daß die NO-Synthese des warmblütigen Organismus ihre Wirkung entfaltet, zur Herstellung von kosmetischen oder dermatologischen Zubereitungen, zur Prophylaxe und Behandlung von entzündlichen Hautzuständen und/oder zum Hautschutz bei empfindlich determinierter trockener Haut
|
DE10111054A1
(de)
*
|
2001-03-06 |
2002-09-12 |
Beiersdorf Ag |
Verwendung von Substanzen, die verhindern, daß die NO-Synthese des warmblütigen Organismus ihre Wirkung entfaltet, zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Stärkung der Barrierefunktion der Haut
|
DE10111052A1
(de)
*
|
2001-03-06 |
2002-09-12 |
Beiersdorf Ag |
Verwendung von Substanzen, die verhindern, daß die NO-Synthase des warmblütigen Organismus ihre Wirkung entfaltet, zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Steigerung der Ceramidbiosynthese
|
US7012098B2
(en)
*
|
2001-03-23 |
2006-03-14 |
Pharmacia Corporation |
Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers
|
BR0310061A
(pt)
*
|
2002-05-16 |
2005-03-01 |
Pharmacia Corp |
Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
|
GB0214147D0
(en)
*
|
2002-06-19 |
2002-07-31 |
Glaxo Group Ltd |
Formulations
|
DK1603872T3
(da)
*
|
2003-03-11 |
2011-07-18 |
Pharmacia Corp |
S-[2-[(1-iminoethyl)amino]ethyl]-2-methyl-l-cystein-maleat-hydrochlorid krystallinsk salt
|
TWI328009B
(en)
|
2003-05-21 |
2010-08-01 |
Glaxo Group Ltd |
Quinoline derivatives as phosphodiesterase inhibitors
|
GB0316290D0
(en)
|
2003-07-11 |
2003-08-13 |
Glaxo Group Ltd |
Novel compounds
|
PE20060272A1
(es)
|
2004-05-24 |
2006-05-22 |
Glaxo Group Ltd |
(2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
|
TWI307630B
(en)
|
2004-07-01 |
2009-03-21 |
Glaxo Group Ltd |
Immunoglobulins
|
GB0418045D0
(en)
|
2004-08-12 |
2004-09-15 |
Glaxo Group Ltd |
Compounds
|
ATE517908T1
(de)
|
2005-01-10 |
2011-08-15 |
Glaxo Group Ltd |
Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände
|
AR053450A1
(es)
|
2005-03-25 |
2007-05-09 |
Glaxo Group Ltd |
Derivados de 3,4-dihidro-pirimido(4,5-d)pirimidin-2-(1h)-ona 1,5,7 trisustituidos como inhibidores de la quinasa p38
|
PE20100737A1
(es)
|
2005-03-25 |
2010-11-27 |
Glaxo Group Ltd |
Nuevos compuestos
|
GB0514809D0
(en)
|
2005-07-19 |
2005-08-24 |
Glaxo Group Ltd |
Compounds
|
AR058109A1
(es)
|
2005-12-20 |
2008-01-23 |
Glaxo Group Ltd |
Acido 3 - (4 - {[4 -(4 -{[3 - (3, 3 - dimetil - 1 - piperidinil)propil]oxi}fenil) - 1 - piperidinil]carbonil} - 1 - naftalenil)propanoico como antagonistas de los receptotres de histamina h1/h3, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamie
|
KR20090003349A
(ko)
|
2006-04-20 |
2009-01-09 |
글락소 그룹 리미티드 |
화합물
|
GB0611587D0
(en)
|
2006-06-12 |
2006-07-19 |
Glaxo Group Ltd |
Novel compounds
|
DK2046787T3
(da)
|
2006-08-01 |
2011-07-18 |
Glaxo Group Ltd |
Pyrazolo[3,4-B]pyridin-forbindelser, og deres anvendelse som PDE4-inhibitorer
|
WO2008147445A2
(en)
*
|
2006-11-09 |
2008-12-04 |
University Of Maryland, Baltimore |
Use of 5,6-dimethylxanthenone-4-acetic acid as an antimicrobial agent
|
AR065804A1
(es)
|
2007-03-23 |
2009-07-01 |
Smithkline Beecham Corp |
Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
|
AU2009325091A1
(en)
|
2008-05-23 |
2010-06-17 |
Panmira Pharmaceuticals, Llc |
5-lipoxygenase-activating protein inhibitor
|
WO2009147190A1
(en)
|
2008-06-05 |
2009-12-10 |
Glaxo Group Limited |
Novel compounds
|
US8163743B2
(en)
|
2008-06-05 |
2012-04-24 |
GlaxoGroupLimited |
4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases
|
WO2010094643A1
(en)
|
2009-02-17 |
2010-08-26 |
Glaxo Group Limited |
Quinoline derivatives and their uses for rhinitis and urticaria
|
ES2542551T3
(es)
|
2009-03-09 |
2015-08-06 |
Glaxo Group Limited |
4-Oxadiazol-2-il-indazoles como inhibidores de PI3 cinasas
|
US8354539B2
(en)
|
2009-03-10 |
2013-01-15 |
Glaxo Group Limited |
Indole derivatives as IKK2 inhibitors
|
EP2408769A1
(en)
|
2009-03-17 |
2012-01-25 |
Glaxo Group Limited |
Pyrimidine derivatives used as itk inhibitors
|
WO2010107958A1
(en)
|
2009-03-19 |
2010-09-23 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
EA201171144A1
(ru)
|
2009-03-19 |
2012-04-30 |
Мерк Шарп Энд Домэ Корп. |
ОПОСРЕДОВАННОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНА ГОМОЛОГА 1 BTB И CNC, ОСНОВНОГО ФАКТОРА ТРАНСКРИПЦИИ С ЛЕЙЦИНОВОЙ МОЛНИЕЙ 1 (Bach1) С ИСПОЛЬЗОВАНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
|
US20120016011A1
(en)
|
2009-03-19 |
2012-01-19 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Connective Tissue Growth Factor (CTGF) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
JP2012520685A
(ja)
|
2009-03-19 |
2012-09-10 |
メルク・シャープ・エンド・ドーム・コーポレイション |
低分子干渉核酸(siNA)を用いたGATA結合タンパク質3(GATA3)遺伝子発現のRNA干渉媒介性阻害
|
JP2012521764A
(ja)
|
2009-03-27 |
2012-09-20 |
メルク・シャープ・エンド・ドーム・コーポレイション |
低分子干渉核酸(siNA)を用いた胸腺間質性リンパ球新生因子(TSLP)遺伝子発現のRNA干渉媒介性阻害
|
US20120004281A1
(en)
|
2009-03-27 |
2012-01-05 |
Merck Sharp & Dohme Corp |
RNA Interference Mediated Inhibition of the Nerve Growth Factor Beta Chain (NGFB) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
WO2010111464A1
(en)
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20120022142A1
(en)
|
2009-03-27 |
2012-01-26 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
EP2411517A2
(en)
|
2009-03-27 |
2012-02-01 |
Merck Sharp&Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
UY32571A
(es)
|
2009-04-24 |
2010-11-30 |
Glaxo Group Ltd |
Compuestos derivados de pirazol amida
|
WO2010122088A1
(en)
|
2009-04-24 |
2010-10-28 |
Glaxo Group Limited |
Pyrazole and triazole carboxamides as crac channel inhibitors
|
SI2899191T1
(sl)
|
2009-04-30 |
2017-11-30 |
Glaxo Group Limited |
Z oksazolom substituirani indazoli kot PI3-kinazni inhibitorji
|
JP5890312B2
(ja)
*
|
2009-10-09 |
2016-03-22 |
ザフゲン,インコーポレイテッド |
肥満治療に用いられるスルホン化合物
|
US20120238571A1
(en)
|
2009-12-03 |
2012-09-20 |
Glaxo Group Limited |
Indazole derivatives as pi 3-kinase
|
JP2013512878A
(ja)
|
2009-12-03 |
2013-04-18 |
グラクソ グループ リミテッド |
新規化合物
|
EP2507223A1
(en)
|
2009-12-03 |
2012-10-10 |
Glaxo Group Limited |
Benzpyrazole derivatives as inhibitors of p13 kinases
|
EP2512438B1
(en)
|
2009-12-16 |
2017-01-25 |
3M Innovative Properties Company |
Formulations and methods for controlling mdi particle size delivery
|
WO2011110575A1
(en)
|
2010-03-11 |
2011-09-15 |
Glaxo Group Limited |
Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
|
GB201007203D0
(en)
|
2010-04-29 |
2010-06-16 |
Glaxo Group Ltd |
Novel compounds
|
EP2614058B1
(en)
|
2010-09-08 |
2015-07-08 |
GlaxoSmithKline Intellectual Property Development Limited |
POLYMORPHS AND SALTS OF N-[5-[4-(5-{[(2R,6S)-2,6-DIMETHYL-4-MORPHOLINYL]METHYL}-& xA;1,3-OXAZOL-2-YL)-1H-INDAZOL-6-YL]-2-(METHYLOXY)-3-PYRIDINYL]METHANESULFONAMIDE
|
ES2602972T3
(es)
|
2010-09-08 |
2017-02-23 |
Glaxosmithkline Intellectual Property Development Limited |
Derivados de indazol para su uso en el tratamiento de infección por virus de la gripe
|
WO2012035055A1
(en)
|
2010-09-17 |
2012-03-22 |
Glaxo Group Limited |
Novel compounds
|
EP2630127A1
(en)
|
2010-10-21 |
2013-08-28 |
Glaxo Group Limited |
Pyrazole compounds acting against allergic, inflammatory and immune disorders
|
ES2532213T3
(es)
|
2010-10-21 |
2015-03-25 |
Glaxo Group Limited |
Compuestos de pirazol que actúan contra afecciones alérgicas, inmunitarias e inflamatorias
|
GB201018124D0
(en)
|
2010-10-27 |
2010-12-08 |
Glaxo Group Ltd |
Polymorphs and salts
|
GB201104153D0
(en)
|
2011-03-11 |
2011-04-27 |
Glaxo Group Ltd |
Novel compounds
|
JP2014507458A
(ja)
|
2011-03-11 |
2014-03-27 |
グラクソ グループ リミテッド |
Sykインヒビターとしてのピリド[3,4−B]ピラジン誘導体
|
CA2920059A1
(en)
|
2013-09-22 |
2015-03-26 |
Calitor Sciences, Llc |
Substituted aminopyrimidine compounds and methods of use
|
US9399637B2
(en)
|
2014-03-28 |
2016-07-26 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
CR20160529A
(es)
|
2014-05-12 |
2017-01-02 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Composiciones farmacéuticas para tratar enfermedades infecciosas
|
GB201512635D0
(en)
|
2015-07-17 |
2015-08-26 |
Ucl Business Plc |
Uses of therapeutic compounds
|
WO2017044434A1
(en)
|
2015-09-11 |
2017-03-16 |
Sunshine Lake Pharma Co., Ltd. |
Substituted heteroaryl compounds and methods of use
|
EP3710006A4
(en)
|
2017-11-19 |
2021-09-01 |
Sunshine Lake Pharma Co., Ltd. |
SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR METHODS OF USE
|
US10751339B2
(en)
|
2018-01-20 |
2020-08-25 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
WO2021191875A1
(en)
|
2020-03-26 |
2021-09-30 |
Glaxosmithkline Intellectual Property Development Limited |
Cathepsin inhibitors for preventing or treating viral infections
|